Finding 500070 (2023-005)

Significant Deficiency
Requirement
AB
Questioned Costs
-
Year
2023
Accepted
2024-09-30
Audit: 322924

AI Summary

  • Core Issue: Lack of internal controls for reviewing fringe benefit journal entries may lead to unallowable expenses being charged to federal research grants.
  • Impacted Requirements: Compliance with Section 200.303 of the Uniform Guidance, which mandates effective internal controls over federal awards.
  • Recommended Follow-Up: Management should implement revised policies to ensure timely review and approval of fringe benefit journal entries.

Finding Text

Finding 2023-005 – Activities Allowed or Unallowed and Allowable Costs/Cost Principles Identification of the federal program: Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.172, Human Genome Research Pass-Through Grantor: University of Chicago Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.242, Mental Health Research Grants Pass-Through Grantors: Rutgers State University, University of Chicago, Johns Hopkins University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.307, Minority Health and Health Disparities Research Pass-Through Grantor: Northwestern University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.350, National Center for Advancing Translational Sciences Pass-Through Grantors: University of Chicago, Duke University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.361, Nursing Research Pass-Through Grantor: Northwestern University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.395, Cancer Treatment Research Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.847, Diabetes, Digestive, and Kidney Diseases Extramural Research Pass-Through Grantors: Northwestern University, Duke University, University of Washington, The Regents of the University of Michigan Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.855, Allergy, Immunology and Transplantation Research Pass-Through Grantor: Northwestern University Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.865, Child Health and Human Development Extramural Research Pass-Through Grantor: University of Chicago Federal Grantor: United States Department of Health and Human Services (HHS) Assistance Listing No.: 93.946, Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs Pass-Through Grantor: Northwestern University Criteria or specific requirement (including statutory, regulatory or other citation): Section 200.303 of the Uniform Guidance states the following regarding internal control: “The non-Federal entity must: (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).” Condition: Management develops a fringe benefit rate annually that is used to allocate fringe benefits to the research and development programs from January 1, 2023 to December 31, 2023. Management did not have internal controls to review the appropriateness of the journal entries recorded for fringe benefit rates. Cause: Management does not have internal controls and policies and procedures to require an appropriate review of fringe benefit journal entries. Effect or potential effect: Unallowable expenses may be inappropriately applied to research and development grants. Questioned costs: None. Context: We tested a sample of 16 fringe benefit journal entries to review. Based on the procedures performed, we identified that the fringe benefit costs were not reviewed timely by the appropriate individual. The Company incurred $673,983 of fringe benefits in 2023 related to Research and Development grants that are included on the Schedule of Expenditures of Federal Awards. Total federal expenditures related to the research and development cluster were $13,409,825 for the year ended December 31, 2023. Identification as a repeat finding, if applicable: This finding is not a repeat finding from the prior year. Recommendation: Management should revise its internal controls and policies to require the appropriate review and approval of fringe benefit journal entries. Views of responsible officials: Management will document a policy to review the updated fringe rate on an annual basis and ensure the fringe expense charged to the grants is in line with the policy and the calculated rate.

Categories

Allowable Costs / Cost Principles

Other Findings in this Audit

  • 499999 2023-001
    Material Weakness
  • 500000 2023-002
    Material Weakness
  • 500001 2023-001
    Material Weakness
  • 500002 2023-002
    Material Weakness
  • 500003 2023-001
    Material Weakness
  • 500004 2023-005
    Significant Deficiency
  • 500005 2023-001
    Material Weakness
  • 500006 2023-005
    Significant Deficiency
  • 500007 2023-001
    Material Weakness
  • 500008 2023-002
    Material Weakness
  • 500009 2023-005
    Significant Deficiency
  • 500010 2023-005
    Significant Deficiency
  • 500011 2023-001
    Material Weakness
  • 500012 2023-005
    Significant Deficiency
  • 500013 2023-001
    Material Weakness
  • 500014 2023-001
    Material Weakness
  • 500015 2023-002
    Material Weakness
  • 500016 2023-005
    Significant Deficiency
  • 500017 2023-001
    Material Weakness
  • 500018 2023-002
    Material Weakness
  • 500019 2023-005
    Significant Deficiency
  • 500020 2023-005
    Significant Deficiency
  • 500021 2023-001
    Material Weakness
  • 500022 2023-001
    Material Weakness
  • 500023 2023-005
    Significant Deficiency
  • 500024 2023-001
    Material Weakness
  • 500025 2023-002
    Material Weakness
  • 500026 2023-004
    Material Weakness
  • 500027 2023-001
    Material Weakness
  • 500028 2023-001
    Material Weakness
  • 500029 2023-005
    Significant Deficiency
  • 500030 2023-001
    Material Weakness
  • 500031 2023-005
    Significant Deficiency
  • 500032 2023-001
    Material Weakness
  • 500033 2023-005
    Significant Deficiency
  • 500034 2023-001
    Material Weakness
  • 500035 2023-005
    Significant Deficiency
  • 500036 2023-001
    Material Weakness
  • 500037 2023-005
    Significant Deficiency
  • 500038 2023-001
    Material Weakness
  • 500039 2023-005
    Significant Deficiency
  • 500040 2023-001
    Material Weakness
  • 500041 2023-005
    Significant Deficiency
  • 500042 2023-001
    Material Weakness
  • 500043 2023-005
    Significant Deficiency
  • 500044 2023-001
    Material Weakness
  • 500045 2023-005
    Significant Deficiency
  • 500046 2023-001
    Material Weakness
  • 500047 2023-005
    Significant Deficiency
  • 500048 2023-001
    Material Weakness
  • 500049 2023-005
    Significant Deficiency
  • 500050 2023-001
    Material Weakness
  • 500051 2023-005
    Significant Deficiency
  • 500052 2023-001
    Material Weakness
  • 500053 2023-001
    Material Weakness
  • 500054 2023-001
    Material Weakness
  • 500055 2023-001
    Material Weakness
  • 500056 2023-001
    Material Weakness
  • 500057 2023-001
    Material Weakness
  • 500058 2023-002
    Material Weakness
  • 500059 2023-003
    Material Weakness
  • 500060 2023-002
    Material Weakness
  • 500061 2023-001
    Material Weakness
  • 500062 2023-001
    Material Weakness
  • 500063 2023-005
    Significant Deficiency
  • 500064 2023-001
    Material Weakness
  • 500065 2023-005
    Significant Deficiency
  • 500066 2023-001
    Material Weakness
  • 500067 2023-005
    Significant Deficiency
  • 500068 2023-001
    Material Weakness
  • 500069 2023-002
    Material Weakness
  • 500071 2023-001
    Material Weakness
  • 500072 2023-005
    Significant Deficiency
  • 500073 2023-001
    Material Weakness
  • 500074 2023-005
    Significant Deficiency
  • 500075 2023-001
    Material Weakness
  • 500076 2023-002
    Material Weakness
  • 500077 2023-001
    Material Weakness
  • 500078 2023-002
    Material Weakness
  • 500079 2023-001
    Material Weakness
  • 500080 2023-005
    Significant Deficiency
  • 500081 2023-002
    Material Weakness
  • 500082 2023-001
    Material Weakness
  • 500083 2023-002
    Material Weakness
  • 500084 2023-001
    Material Weakness
  • 500085 2023-001
    Material Weakness
  • 500086 2023-001
    Material Weakness
  • 500087 2023-005
    Significant Deficiency
  • 500088 2023-001
    Material Weakness
  • 500089 2023-001
    Material Weakness
  • 500090 2023-003
    Material Weakness
  • 500091 2023-001
    Material Weakness
  • 500092 2023-002
    Material Weakness
  • 500093 2023-005
    Significant Deficiency
  • 500094 2023-001
    Material Weakness
  • 500095 2023-002
    Material Weakness
  • 500096 2023-005
    Significant Deficiency
  • 500097 2023-001
    Material Weakness
  • 1076441 2023-001
    Material Weakness
  • 1076442 2023-002
    Material Weakness
  • 1076443 2023-001
    Material Weakness
  • 1076444 2023-002
    Material Weakness
  • 1076445 2023-001
    Material Weakness
  • 1076446 2023-005
    Significant Deficiency
  • 1076447 2023-001
    Material Weakness
  • 1076448 2023-005
    Significant Deficiency
  • 1076449 2023-001
    Material Weakness
  • 1076450 2023-002
    Material Weakness
  • 1076451 2023-005
    Significant Deficiency
  • 1076452 2023-005
    Significant Deficiency
  • 1076453 2023-001
    Material Weakness
  • 1076454 2023-005
    Significant Deficiency
  • 1076455 2023-001
    Material Weakness
  • 1076456 2023-001
    Material Weakness
  • 1076457 2023-002
    Material Weakness
  • 1076458 2023-005
    Significant Deficiency
  • 1076459 2023-001
    Material Weakness
  • 1076460 2023-002
    Material Weakness
  • 1076461 2023-005
    Significant Deficiency
  • 1076462 2023-005
    Significant Deficiency
  • 1076463 2023-001
    Material Weakness
  • 1076464 2023-001
    Material Weakness
  • 1076465 2023-005
    Significant Deficiency
  • 1076466 2023-001
    Material Weakness
  • 1076467 2023-002
    Material Weakness
  • 1076468 2023-004
    Material Weakness
  • 1076469 2023-001
    Material Weakness
  • 1076470 2023-001
    Material Weakness
  • 1076471 2023-005
    Significant Deficiency
  • 1076472 2023-001
    Material Weakness
  • 1076473 2023-005
    Significant Deficiency
  • 1076474 2023-001
    Material Weakness
  • 1076475 2023-005
    Significant Deficiency
  • 1076476 2023-001
    Material Weakness
  • 1076477 2023-005
    Significant Deficiency
  • 1076478 2023-001
    Material Weakness
  • 1076479 2023-005
    Significant Deficiency
  • 1076480 2023-001
    Material Weakness
  • 1076481 2023-005
    Significant Deficiency
  • 1076482 2023-001
    Material Weakness
  • 1076483 2023-005
    Significant Deficiency
  • 1076484 2023-001
    Material Weakness
  • 1076485 2023-005
    Significant Deficiency
  • 1076486 2023-001
    Material Weakness
  • 1076487 2023-005
    Significant Deficiency
  • 1076488 2023-001
    Material Weakness
  • 1076489 2023-005
    Significant Deficiency
  • 1076490 2023-001
    Material Weakness
  • 1076491 2023-005
    Significant Deficiency
  • 1076492 2023-001
    Material Weakness
  • 1076493 2023-005
    Significant Deficiency
  • 1076494 2023-001
    Material Weakness
  • 1076495 2023-001
    Material Weakness
  • 1076496 2023-001
    Material Weakness
  • 1076497 2023-001
    Material Weakness
  • 1076498 2023-001
    Material Weakness
  • 1076499 2023-001
    Material Weakness
  • 1076500 2023-002
    Material Weakness
  • 1076501 2023-003
    Material Weakness
  • 1076502 2023-002
    Material Weakness
  • 1076503 2023-001
    Material Weakness
  • 1076504 2023-001
    Material Weakness
  • 1076505 2023-005
    Significant Deficiency
  • 1076506 2023-001
    Material Weakness
  • 1076507 2023-005
    Significant Deficiency
  • 1076508 2023-001
    Material Weakness
  • 1076509 2023-005
    Significant Deficiency
  • 1076510 2023-001
    Material Weakness
  • 1076511 2023-002
    Material Weakness
  • 1076512 2023-005
    Significant Deficiency
  • 1076513 2023-001
    Material Weakness
  • 1076514 2023-005
    Significant Deficiency
  • 1076515 2023-001
    Material Weakness
  • 1076516 2023-005
    Significant Deficiency
  • 1076517 2023-001
    Material Weakness
  • 1076518 2023-002
    Material Weakness
  • 1076519 2023-001
    Material Weakness
  • 1076520 2023-002
    Material Weakness
  • 1076521 2023-001
    Material Weakness
  • 1076522 2023-005
    Significant Deficiency
  • 1076523 2023-002
    Material Weakness
  • 1076524 2023-001
    Material Weakness
  • 1076525 2023-002
    Material Weakness
  • 1076526 2023-001
    Material Weakness
  • 1076527 2023-001
    Material Weakness
  • 1076528 2023-001
    Material Weakness
  • 1076529 2023-005
    Significant Deficiency
  • 1076530 2023-001
    Material Weakness
  • 1076531 2023-001
    Material Weakness
  • 1076532 2023-003
    Material Weakness
  • 1076533 2023-001
    Material Weakness
  • 1076534 2023-002
    Material Weakness
  • 1076535 2023-005
    Significant Deficiency
  • 1076536 2023-001
    Material Weakness
  • 1076537 2023-002
    Material Weakness
  • 1076538 2023-005
    Significant Deficiency
  • 1076539 2023-001
    Material Weakness

Programs in Audit

ALN Program Name Expenditures
93.391 Covid-19 Activities to Support State, Tribal, Local and Territorial (stlt) Health Department Response to Public Health Or Healthcare Crisis $1.26M
93.394 Cancer Detection and Diagnosis Research $816,528
21.027 Covid-19 Coronavirus State and Local Fiscal Recovery Funds $609,195
93.310 Trans-Nih Research Support $313,490
16.560 National Institute of Justice Research, Evaluation, and Development Project Grants $187,525
93.994 Maternal and Child Health Services Block Grant to the States $168,656
93.323 Covid-19 Epidemiology and Laboratory Capacity for Infectious Diseases (elc) $167,045
93.350 National Center for Advancing Translational Sciences $164,703
93.368 21st Century Cures Act - Precision Medicine Initiative $94,609
93.838 Lung Diseases Research $93,061
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $80,571
93.855 Allergy and Infectious Diseases Research $72,630
93.351 Research Infrastructure Programs $67,407
93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health $64,097
93.396 Cancer Biology Research $56,813
12.420 Military Medical Research and Development $55,493
93.226 Research on Healthcare Costs, Quality and Outcomes $36,564
93.865 Child Health and Human Development Extramural Research $29,653
93.393 Cancer Cause and Prevention Research $17,681
93.307 Minority Health and Health Disparities Research $15,122
93.172 Human Genome Research $15,121
93.397 Cancer Centers Support Grants $14,078
93.889 National Bioterrorism Hospital Preparedness Program $13,333
93.866 Aging Research $11,855
93.273 Alcohol Research Programs $10,732
14.218 Community Development Block Grants/entitlement Grants $10,044
93.837 Cardiovascular Diseases Research $8,921
93.361 Nursing Research $7,645
93.667 Social Services Block Grant $7,551
93.839 Blood Diseases and Resources Research $3,217
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $597
93.395 Cancer Treatment Research $512
93.946 Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs $-697
93.859 Biomedical Research and Research Training $-2,184
93.242 Mental Health Research Grants $-20,481